- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05536752
QA102 Fase II-onderzoek bij proefpersonen met droge AMD (AMEND)
Een fase 2, dubbel gemaskeerd, gerandomiseerd, placebogecontroleerd, dosis-responsonderzoek ter beoordeling van de veiligheid en werkzaamheid van QA102 bij proefpersonen met droge leeftijdsgebonden maculaire degeneratie (AMD)
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85021
- Associated Retina Consultants
-
-
California
-
Mountain View, California, Verenigde Staten, 94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena, California, Verenigde Staten, 91107
- California Eye Specialists Medical Group
-
Redlands, California, Verenigde Staten, 91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, Verenigde Staten, 80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach, Florida, Verenigde Staten, 33064
- Advanced Research
-
Fort Myers, Florida, Verenigde Staten, 33912
- National Ophthalmic Research Institute
-
Miami, Florida, Verenigde Staten, 33143
- MedEye Associates
-
Pensacola, Florida, Verenigde Staten, 32503
- Retina Specialty Institute
-
Pinellas Park, Florida, Verenigde Staten, 33782
- Eye Associates of Pinellas
-
Sarasota, Florida, Verenigde Staten, 34239
- Sarasota Retina Institute
-
Winter Haven, Florida, Verenigde Staten, 33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta, Georgia, Verenigde Staten, 30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest, Illinois, Verenigde Staten, 60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe, Louisiana, Verenigde Staten, 71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21209
- The Retina Care Center
-
Hagerstown, Maryland, Verenigde Staten, 21740
- Cumberland Valley Retina Consultants
-
Hagerstown, Maryland, Verenigde Staten, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester, Massachusetts, Verenigde Staten, 01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene, Oregon, Verenigde Staten, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, Verenigde Staten, 16507
- Erie Retina Research
-
-
Texas
-
Abilene, Texas, Verenigde Staten, 79606
- Retina Research Institute of Texas
-
Austin, Texas, Verenigde Staten, 78705
- Austin Research Center for Retina
-
Dallas, Texas, Verenigde Staten, 75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano, Texas, Verenigde Staten, 75075
- Texas Retina Associates - Plano
-
San Antonio, Texas, Verenigde Staten, 78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84107
- Rocky Mountain Retina Consultants
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
Experimenteel: QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
Placebo-vergelijker: Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
Tijdsspanne: Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean Rate of GA Growth
Tijdsspanne: Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- QA102-CS201
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .